-
公开(公告)号:USRE39679E1
公开(公告)日:2007-06-05
申请号:US11356423
申请日:2006-02-16
申请人: Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emile J. B. Calvello , David M. Zawrotny , Parthasarathl Rajagopalan
发明人: Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emile J. B. Calvello , David M. Zawrotny , Parthasarathl Rajagopalan
IPC分类号: C07D267/22 , C07D281/18 , C07D267/02 , C07D279/00 , C07D265/34
CPC分类号: C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
-
公开(公告)号:US20130289027A1
公开(公告)日:2013-10-31
申请号:US13980085
申请日:2012-01-23
IPC分类号: C07D217/24 , A61K45/06 , C07D401/12 , A61K31/4725 , A61K31/541 , A61K31/5377 , A61K31/472 , C07D405/04
CPC分类号: C07D217/24 , A61K31/472 , A61K31/4725 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/14 , C07D413/14
摘要: Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the Human Immunodeficiency Virus (HIV).
摘要翻译: 本发明提供了其化合物及其药学上可接受的盐,其药物组合物,其制备方法及其用于治疗由逆转录病毒病毒家族成员(例如人类免疫缺陷病毒(HIV))介导的病毒感染的用途。
-
公开(公告)号:US06713471B1
公开(公告)日:2004-03-30
申请号:US09594954
申请日:2000-06-15
申请人: Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Simon Haydar , Wenting Chen , Christopher D. Mc Clung , Emilie J. B. Calvello , David M. Zawrotny
发明人: Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Simon Haydar , Wenting Chen , Christopher D. Mc Clung , Emilie J. B. Calvello , David M. Zawrotny
IPC分类号: C07D26722
CPC分类号: C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
摘要翻译: 本发明涉及由结构式(I)表示的某些新化合物或其药学上可接受的盐形式,其中R 1,R 5,R 6a,R 6b,R 7,R 7, <8>,R 9,X,b,k,m和n,这里描述虚线。 本发明还涉及包含这些新化合物作为活性成分的药物制剂,以及新型化合物及其制剂在治疗某些疾病中的用途。 本发明的化合物是血清素激动剂和拮抗剂,可用于控制或预防中枢神经系统疾病,包括肥胖症,焦虑症,抑郁症,精神病,精神分裂症,睡眠障碍,性障碍,偏头痛,与头痛相关的病症,社交恐怖症 ,以及胃肠道疾病如胃肠道运动功能障碍。
-
公开(公告)号:US06552017B1
公开(公告)日:2003-04-22
申请号:US09595250
申请日:2000-06-15
申请人: Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. Mc Clung , Emilie J. B. Calvello , David M. Zawrotny
发明人: Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. Mc Clung , Emilie J. B. Calvello , David M. Zawrotny
IPC分类号: C07D48700
CPC分类号: C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
摘要翻译: 本发明涉及由结构式(I)表示的某些新化合物或其药学上可接受的盐形式,其中R1,R5,R6a,R6b,R7,R8,R9,X,b,k,m和n以及 这里描述了虚线。 本发明还涉及包含这些新化合物作为活性成分的药物制剂,以及新型化合物及其制剂在治疗某些疾病中的用途。 本发明的化合物是血清素激动剂和拮抗剂,可用于控制或预防中枢神经系统疾病,包括肥胖症,焦虑症,抑郁症,精神病,精神分裂症,睡眠障碍,性障碍,偏头痛,与头痛相关的病症,社交恐怖症 ,以及胃肠道疾病如胃肠道运动功能障碍。
-
公开(公告)号:USRE39680E1
公开(公告)日:2007-06-05
申请号:US11356421
申请日:2006-02-16
申请人: Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emile J. B. Calvello , David M. Zawrotny , Parthasarathl Rajagopalan
发明人: Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emile J. B. Calvello , David M. Zawrotny , Parthasarathl Rajagopalan
IPC分类号: C07D487/00 , C07D243/00 , C07D491/00 , C07D241/36 , A61K31/55
CPC分类号: C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
摘要翻译: 本发明涉及由结构式(I)表示的某些新化合物或其药学上可接受的盐形式,其中R 1,R 5,R 6, R 6b,R 6b,R 7,R 8,R 9,X,b,k, m和n,虚线在此描述。 本发明还涉及包含这些新化合物作为活性成分的药物制剂,以及新型化合物及其制剂在治疗某些疾病中的用途。 本发明的化合物是血清素激动剂和拮抗剂,可用于控制或预防中枢神经系统疾病,包括肥胖症,焦虑症,抑郁症,精神病,精神分裂症,睡眠障碍,性障碍,偏头痛,与头痛相关的病症,社交恐怖症 ,以及胃肠道疾病如胃肠道运动功能障碍。
-
公开(公告)号:US07183282B2
公开(公告)日:2007-02-27
申请号:US11375125
申请日:2006-03-14
申请人: Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael G. Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emilie J. Calvello , David M. Zawrotny
发明人: Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael G. Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emilie J. Calvello , David M. Zawrotny
IPC分类号: C07D471/04 , A61K31/4985
CPC分类号: C07D471/06 , C07D221/18 , C07D223/32 , C07D471/16 , C07D487/06 , C07D491/06 , C07D495/06 , C07D513/06 , C07D513/16 , C07D519/00
摘要: The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
-
公开(公告)号:US20060148808A1
公开(公告)日:2006-07-06
申请号:US11375125
申请日:2006-03-14
申请人: Albert Robichaud , Taekyu Lee , Wei Deng , Ian Mitchell , Michael Yang , Simon Haydar , Wenting Chen , Christopher McClung , Emilie Calvello , David Zawrotny
发明人: Albert Robichaud , Taekyu Lee , Wei Deng , Ian Mitchell , Michael Yang , Simon Haydar , Wenting Chen , Christopher McClung , Emilie Calvello , David Zawrotny
IPC分类号: A61K31/498 , C07D487/14
CPC分类号: C07D471/06 , C07D221/18 , C07D223/32 , C07D471/16 , C07D487/06 , C07D491/06 , C07D495/06 , C07D513/06 , C07D513/16 , C07D519/00
摘要: The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
摘要翻译: 本发明涉及可用于治疗由结构式(I)或其药学上可接受的盐形式表示的成瘾行为和睡眠障碍的化合物,其中R 1,R 5, R 6a,R 6b,R 7,R 8,R 9, X,b,k,m和n,这里描述虚线。 用于治疗本发明的方法中的化合物是血清素激动剂和拮抗剂,并且可用于控制或预防中枢神经系统疾病,包括上瘾行为和睡眠障碍。
-
公开(公告)号:US07071186B2
公开(公告)日:2006-07-04
申请号:US10787941
申请日:2004-02-26
申请人: Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael G. Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emilie J. Calvello , David M. Zawrotny
发明人: Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael G. Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emilie J. Calvello , David M. Zawrotny
IPC分类号: A61P25/00
CPC分类号: C07D471/06 , C07D221/18 , C07D223/32 , C07D471/16 , C07D487/06 , C07D491/06 , C07D495/06 , C07D513/06 , C07D513/16 , C07D519/00
摘要: The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
-
公开(公告)号:US09029391B2
公开(公告)日:2015-05-12
申请号:US13980085
申请日:2012-01-23
IPC分类号: A61K31/472 , A61K31/4725 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D401/12 , C07D217/24 , C07D401/04 , C07D401/14 , C07D405/04 , C07D413/14 , C07D405/14
CPC分类号: C07D217/24 , A61K31/472 , A61K31/4725 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/14 , C07D413/14
摘要: Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the Human Immunodeficiency Virus (HIV).
摘要翻译: 本发明提供了其化合物及其药学上可接受的盐,其药物组合物,其制备方法及其用于治疗由逆转录病毒病毒家族成员(例如人类免疫缺陷病毒(HIV))介导的病毒感染的用途。
-
-
-
-
-
-
-
-